Tagged with IEM

Middle East & Africa As profit margins in established markets decreased, “pharmerging markets” became the new El Dorado for pharma and medtech companies in the 2010s. Many put in big investments only to discover that the volatility of these geographies often meant that the expected returns did not materialise. However, especially post-COVID, emerging markets…

Global The world’s top 10 medical technology companies for 2022 according to Medical Product Outsourcing (MPO). Abbott leads the way, followed by Medtronic, J&J, and Siemens Healthineers. Recent PharmaBoardroom interviews with some of these companies’ leading executives include Hugo F. Villegas, SVP & President, Canada & Latin America at Medtronic, Eman…

Spain Spanish mid-cap Esteve is selling a 26 percent stake in the company to German private investment firm Lubea, a move it says will supply the necessary funds to further pursue its redefined company strategy while stepping up growth and allowing for additional international expansion. Expansion: Products and Geographies Esteve, a…

UAE Following a turbulent few years for the healthcare industry, especially in the Middle East and Africa region, Siemens Healthineers’ Ole Per Maloy explains how the medtech giant has pivoted towards comprehensive cancer care and rolled out several innovative access initiatives to ensure that patients throughout the region can obtain accessible…

LatAm Latin America is a rapidly growing market for the global medtech industry, offering significant opportunities. With a population of over 650 million people, the region boasts a large and growing middle class that are showing increasing demand for high-quality healthcare services and medical technologies. In recent years, the Latin American…

LatAm Guilherme Marques, president of Siemens Healthineers LatAm, discusses the health tech giant’s regional strategy, covering how the firm rides out the region’s economic and political storms, its participation in disease screening campaigns, digitalisation uptake, oncology integration, and much more.   Despite the uncertainty of [LatAm] markets – due to inflation,…

Egypt All the latest news stories from Egypt’s healthcare and life sciences industry, including Egypt’s health insurance authority’s plans to add 100 new medical services, how the COVID-19 Omicron variant threatens to overwhelm the country’s healthcare system, and a new tie-up between Siemens Healthineers and Alameda Group.   Egypt’s health insurance…

Saudi Arabia The Saudi medtech market was valued at USD 2.25 billion in 2017 and is expected to reach USD 3.87 billion at a CAGR of 9.5 percent by 2023, according to Market Research Future. Like other parts of the Saudi healthcare continuum, the country’s medtech industry is extremely dynamic and changing…

Denmark Medtech The DKK 56bn (EUR 7.5bn) Danish medtech industry employs 15,200 workers, accounts for 7.4 percent of Danish business and industry’s total research investments, contributes to 1.4 percent of national GDP, and exports DKK 18.2bn (EUR 2.4bn) worth of products annually. Here are five key trends affecting this important sector.  …

Denmark In a wide-ranging and candid conversation, Siemens Healthineers’ Tisha Boatman discusses uprooting from the US to Denmark, how Danish hospital tendering needs to evolve beyond price considerations alone, the challenges and opportunities of the Varian integration in her region, and shares some advice for other female executives in the medtech…

Saudi Arabia Siemens Healthineers’ CEO for the Middle East and Southern and Eastern Africa, Ole Per Maloy, outlines the company’s different business models in the region, how it chooses partners in markets where Siemens Healthineers previously operated indirectly, and explains how the Varian acquisition will allow the organisation to provide comprehensive cancer…

Global PharmaBoardroom has spread its wings far and wide in 2021 (albeit digitally!), from well covered markets such as Singapore and Switzerland to new frontiers like Saudi Arabia. Our interviewees have ranged from regional Big Pharma and medtech general managers, to the CEOs of important local players, and the heads of…